REG - AOTI, Inc. - 2024 Annual Report and Notice of AGM

AotiAnnouncement

27/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250527:nRSa0225Ka&default-theme=true

RNS Number : 0225K  AOTI, Inc.  27 May 2025

27 May 2025

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

2024 Annual Report and Notice of Annual General Meeting

 

AOTI, INC. (AIM: AOTI), a medical technology group focused on the durable
healing of wounds and the prevention of amputations, announces that electronic
copies of the Company's Annual Report and Financial Statements for the year
ended 31 December 2024, together with the 2025 Notice of Annual General
Meeting (the 'Notice'), Form of Instruction and Proxy form swill shortly be
available on the Company's website at:

https://aotinc.net/investors/financial-reports-publications-2/
(https://aotinc.net/investors/financial-reports-publications-2/)

The Annual General Meeting ('AGM') will be held at 10:00 British Summer Time
(BST) on Wednesday, 25 June 2025 at Temple Chambers, 3 - 7 Temple Avenue,
London, EC4Y 0DT, United Kingdom.

Shareholders are encouraged to vote on the resolutions to be put to the AGM by
proxy whether or not they intend to attend. Voting by proxy prior to the AGM
does not affect shareholders' right to attend the AGM and vote in person
should they so wish.  Holders of Depositary Interests will be sent a Form of
Instruction for voting their shares and all other shareholders will be sent
the Notice and Proxy form; with all items posted on or around 27 May 2025.

Full details of the operation and arrangements for the AGM are set out in the
Notice.

 

ENDS

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer   +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer     ir@aotinc.net (mailto:ir@aotinc.net)

 Peel Hunt LLP (Nominated Adviser and Broker)

 Dr. Christopher Golden, James Steel           +44 (0)20 7418 8900

 FTI Consulting (Financial PR & IR)

 Ben Atwell, Simon Conway,                     +44 (0)20 3727 1000

 Natalie Garland-Collins, Alex Davis           AOTI@fticonsulting.com (mailto:AOTI@fticonsulting.com)

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomised controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalisations and 71 per cent reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA), Europe
(CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products
Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net
(http://www.aotinc.net)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSBBGDUGUDDGUX